FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293063334> ?p ?o ?g. }

• W4293063334 endingPage "2506" @default.
• W4293063334 startingPage "2493" @default.
• W4293063334 abstract "The neoadjuvant setting provides immense opportunities for translational research and drug development. The acceptance of pathological complete response (pCR) as a surrogate endpoint for clinical benefit has led to the widespread use of neoadjuvant treatment. Optimal neoadjuvant therapies are determined based on their ability to achieve the highest rates of pCR. Predicted rates of pCR for triple negative breast cancer (TNBC) treated with sequential taxane/anthracycline regimens range from 35% to 48%. With the addition of a platinum agent pCR rates of 55% are predicted. Further increases have been observed with the addition of immune checkpoint inhibitors to this standard chemotherapy backbone. In the pivotal KEYNOTE-522 clinical trial pCR rates of 65% and 69% were reported for chemotherapy plus pembrolizumab in the overall and PD-L1-positive subgroup respectively. The role of the neoadjuvant chemotherapy is less clear in hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer. In general, HR-positive cancers have the least chance of achieving a pCR after neoadjuvant chemotherapy, especially if they are low-grade. If neoadjuvant chemotherapy is given for high-risk HR-positive, HER2-negative breast cancer, standard adjuvant anthracycline/taxane regimens are appropriate. Optimum endocrine therapy is the standard-of-care in the adjuvant setting regardless of pCR. There are several genomic signatures available to guide decisions regarding adjuvant chemotherapy use however these assays are not routinely used in the neoadjuvant setting. For high-risk patients meeting the criteria for the monarchE trial adjuvant abemaciclib in addition to endocrine therapy is associated with an improvement in disease free survival (DFS) at 3 years. Based on the OlympiA trial patients with germline BRCA mutations should be considered for adjuvant olaparib therapy. In this article we review neoadjuvant clinical trials that guide optimum treatment options for TNBC and HR-positive, HER2-negative breast cancer." @default.
• W4293063334 created "2022-08-26" @default.
• W4293063334 creator A5002952059 @default.
• W4293063334 creator A5076556096 @default.
• W4293063334 date "2022-08-01" @default.
• W4293063334 modified "2023-10-14" @default.
• W4293063334 title "Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights" @default.
• W4293063334 cites W1486001319 @default.
• W4293063334 cites W1701849548 @default.
• W4293063334 cites W1949597673 @default.
• W4293063334 cites W1955397179 @default.
• W4293063334 cites W1993122592 @default.
• W4293063334 cites W2075894019 @default.
• W4293063334 cites W2109079833 @default.
• W4293063334 cites W2116522870 @default.
• W4293063334 cites W2125396123 @default.
• W4293063334 cites W2128458647 @default.
• W4293063334 cites W2138734774 @default.
• W4293063334 cites W2147415463 @default.
• W4293063334 cites W2153158488 @default.
• W4293063334 cites W2164774797 @default.
• W4293063334 cites W2585697071 @default.
• W4293063334 cites W2605509116 @default.
• W4293063334 cites W2606920283 @default.
• W4293063334 cites W2618058692 @default.
• W4293063334 cites W2774580734 @default.
• W4293063334 cites W2805734855 @default.
• W4293063334 cites W2807418950 @default.
• W4293063334 cites W2897422388 @default.
• W4293063334 cites W2902218997 @default.
• W4293063334 cites W2915774478 @default.
• W4293063334 cites W2946550606 @default.
• W4293063334 cites W2999400187 @default.
• W4293063334 cites W3005738019 @default.
• W4293063334 cites W3006134372 @default.
• W4293063334 cites W3006930853 @default.
• W4293063334 cites W3008792561 @default.
• W4293063334 cites W3029650267 @default.
• W4293063334 cites W3030003053 @default.
• W4293063334 cites W3087393791 @default.
• W4293063334 cites W3121634845 @default.
• W4293063334 cites W3122861570 @default.
• W4293063334 cites W3148345241 @default.
• W4293063334 cites W3165576985 @default.
• W4293063334 cites W3168654539 @default.
• W4293063334 cites W3173061082 @default.
• W4293063334 cites W3175173749 @default.
• W4293063334 cites W3187883378 @default.
• W4293063334 cites W3204414803 @default.
• W4293063334 cites W3206169364 @default.
• W4293063334 cites W3213834237 @default.
• W4293063334 cites W4200019473 @default.
• W4293063334 cites W4200350191 @default.
• W4293063334 cites W4210452542 @default.
• W4293063334 cites W4213010786 @default.
• W4293063334 cites W4223904426 @default.
• W4293063334 cites W4225966173 @default.
• W4293063334 cites W4226051140 @default.
• W4293063334 cites W4226218519 @default.
• W4293063334 cites W4229079181 @default.
• W4293063334 cites W4232349440 @default.
• W4293063334 cites W4233358210 @default.
• W4293063334 cites W4243051815 @default.
• W4293063334 doi "https://doi.org/10.2147/cmar.s341466" @default.
• W4293063334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35999966" @default.
• W4293063334 hasPublicationYear "2022" @default.
• W4293063334 type Work @default.
• W4293063334 citedByCount "1" @default.
• W4293063334 countsByYear W42930633342023 @default.
• W4293063334 crossrefType "journal-article" @default.
• W4293063334 hasAuthorship W4293063334A5002952059 @default.
• W4293063334 hasAuthorship W4293063334A5076556096 @default.
• W4293063334 hasBestOaLocation W42930633341 @default.
• W4293063334 hasConcept C121608353 @default.
• W4293063334 hasConcept C126322002 @default.
• W4293063334 hasConcept C143998085 @default.
• W4293063334 hasConcept C2776694085 @default.
• W4293063334 hasConcept C2776802502 @default.
• W4293063334 hasConcept C2777511904 @default.
• W4293063334 hasConcept C2777701055 @default.
• W4293063334 hasConcept C2778292576 @default.
• W4293063334 hasConcept C2779786085 @default.
• W4293063334 hasConcept C2780057760 @default.
• W4293063334 hasConcept C2781190966 @default.
• W4293063334 hasConcept C530470458 @default.
• W4293063334 hasConcept C535046627 @default.
• W4293063334 hasConcept C71924100 @default.
• W4293063334 hasConceptScore W4293063334C121608353 @default.
• W4293063334 hasConceptScore W4293063334C126322002 @default.
• W4293063334 hasConceptScore W4293063334C143998085 @default.
• W4293063334 hasConceptScore W4293063334C2776694085 @default.
• W4293063334 hasConceptScore W4293063334C2776802502 @default.
• W4293063334 hasConceptScore W4293063334C2777511904 @default.
• W4293063334 hasConceptScore W4293063334C2777701055 @default.
• W4293063334 hasConceptScore W4293063334C2778292576 @default.
• W4293063334 hasConceptScore W4293063334C2779786085 @default.
• W4293063334 hasConceptScore W4293063334C2780057760 @default.
• W4293063334 hasConceptScore W4293063334C2781190966 @default.

• next